Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 4bx39 | — |
adult dose administered inadvertently to adolescent; adult dose administered inadvertently to adolescent; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult product administered to child in a 18-year-old male patient who received HBV (Engerix B adult) (batch number 4bx39, expiry date 29-JUL-2027) for prophylaxis. On 27-MAR-2025, the patient received Engerix B adult. On 27-MAR-2025, an unknown time after receiving Engerix B adult, the patient experienced adult product administered to child (Verbatim: adult dose administered inadvertently to adolescent) and overdose (Verbatim: adult dose administered inadvertently to adolescent). The outcome of the adult product administered to child and overdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 27-MAR-2025 Other HCP reported that an adult dose of Engerix B was administered to an 18 year old patient today, which led to adult product administered to child and overdose.